The UC space is highly diversified with a number of molecules approved. In October 2023, the FDA approved Omvoh (mirikizumab), an interleukin-23 antagonist developed by Eli Lilly. It is indicated ...

Other significant developments include promising phase 3 trial results for alopecia areata and the FDA's approval of Omvoh, which, along with solid earnings, position the company favorably even as ...

We recently published a list of 15 Dividend Zombies to Invest in. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other dividend zombies to ...

along with approval for Omvoh for managing moderately to severely active Crohn’s disease. Eli Lilly and Company (NYSE:LLY), one of the best dividend zombies, has been paying dividends to ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease. This approval is the fourth ...

Data captured from pediatric patients revealed a relationship between high burden of common infection episodes in early life and increased risk for moderate to severe infections in later childhood ...

This article delves into the three approved assets in this class – AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Omvoh (mirikizumab), and J&J’s Tremfya (guselkumab) – and explores how ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the first drug in the class available in both intravenous and subcutaneous ...

as well as approval for Omvoh for managing moderately to severely active Crohn’s disease. Eli Lilly and Company (NYSE:LLY)’s rapid growth in recent years has been largely fueled by the success ...

Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for ...

2. Omvoh: Recently approved for Crohn’s disease, expanding Eli Lilly’s presence in the inflammatory bowel disease (IBD) space. 3. Ebglyss: Approved for atopic dermatitis, further diversifying ...